Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization

Status Withdrawn

Clinical Trial Summary

The purpose of the study is to test the investigational drug Gamunex-C on the growth of blood vessels over the cornea. This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center at the University of Utah.

The cornea is the clear outer front part of the eye. In corneal neovascularization, blood vessels grow over the cornea. Corneal neovascularization and ocular anterior segment inflammations are sight-threatening conditions. Lipid deposition and edema with subsequent scar formation can compromise corneal clarity irreversibly. Corneal neovascularization is also a well recognized risk factor for corneal graft failure. In its natural state, the cornea is a site of immune privilege well suited to tissue transplantation. Once vascularized, there is direct exposure of corneal antigens to circulating host immune mechanisms greatly increasing the chance of rejection [Collaborative Corneal Transplantation Study].

Melting or inflammation in the anterior chamber, cornea, or ocular surface can cause irreversible scarring or destruction of the optical elements of the eye, which can compromise vision.

Current standard of care for such conditions includes use of topical steroids and sometimes immunosuppressants (e.g., cyclosporine). These do not address a common underlying corneal neovascularization or melting.

This is a Phase 1 clinical trial of subconjunctival IVIg (Gamunex-C) injection for treatment of corneal neovascularization in the setting of corneal transplantation with neovascularization. Candidates for corneal transplantation with corneal neovascularization in one or more quadrants crossing more than 0.5mm over the limbus will be identified for inclusion in our study.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02042027
Study type	Interventional
Source	University of Utah
Contact
Status	Withdrawn
Phase	Phase 1
Start date	July 2014
Completion date	July 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00555594` - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization	Phase 2/Phase 3
Completed	`NCT00004430` - Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization	N/A
Completed	`NCT00769145` - Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery	Phase 1
Completed	`NCT01257750` - Treatment of Corneal Neovascularization With Topical Pazopanib	Phase 1/Phase 2
Recruiting	`NCT04787471` - Corneal Crosslinking for Treatment of Corneal Neovascularization	Phase 2/Phase 3
Not yet recruiting	`NCT06412718` - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Active, not recruiting	`NCT00992849` - Bevacizumab for the Treatment of Corneal Neovascularization	Phase 2
Withdrawn	`NCT00515684` - Corneal Thinning During Topical Bevacizumab Therapy	N/A
Terminated	`NCT02797704` - Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization	Phase 1/Phase 2
Terminated	`NCT01868360` - Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea	Phase 1
Recruiting	`NCT04215393` - An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization	Phase 1
Completed	`NCT00797303` - The Effect of Bevacizumab on Corneal Neovascularization	Phase 4
Recruiting	`NCT05659940` - Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Completed	`NCT00559936` - Topical Avastin for Treatment of Corneal Neovascularization	Phase 1
Completed	`NCT01072357` - Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	Phase 1/Phase 2
Recruiting	`NCT04620109` - Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment	Phase 1
Completed	`NCT00512876` - Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization	N/A
Recruiting	`NCT05011916` - The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization	Phase 1/Phase 2
Completed	`NCT01996826` - A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	Phase 1/Phase 2
Terminated	`NCT00915590` - Topical IL-1-Ra for Treatment of Corneal Neovascularization	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms